Cargando…

Rituximab treatment for refractory nephrotic syndrome in adults: a multicenter retrospective study

BACKGROUND: The treatment of refractory nephrotic syndrome (RNS) is full of challenges and the role of rituximab (RTX) is not well-established, thus this study aims to demonstrate the role of RTX in RNS. METHODS: This was a multicenter retrospective study of all adult patients receiving RTX for RNS....

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Xiaoyan, Fang, Lu, Sheng, Lili, Zhou, Xun, Bai, Shoujun, Zang, Xiujuan, Wang, Yakun, Li, Mengke, Lv, Zexin, Zhong, Qin, Yang, Xinyu, Wang, Yishu, Hu, Yan, Yan, Danying, Shi, Yingfeng, Chen, Hui, Li, Jinqing, Tao, Min, Zhuang, Shougang, Wang, Yi, Liu, Na
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10367573/ https://www.ncbi.nlm.nih.gov/pubmed/37482915 http://dx.doi.org/10.1080/0886022X.2023.2237124

Ejemplares similares

A retrospective study of baseline peritoneal transport character and left ventricular hypertrophy in incident peritoneal dialysis patients: interrelationship and prognostic impacts
por: Wang, Yi, et al.
Publicado: (2023)

Enhancer of zeste homolog 2 promotes renal fibrosis after acute kidney injury by inducing epithelial-mesenchymal transition and activation of M2 macrophage polarization
por: Zhou, Xun, et al.
Publicado: (2023)

Histone deacetylase 8 inhibition prevents the progression of peritoneal fibrosis by counteracting the epithelial-mesenchymal transition and blockade of M2 macrophage polarization
por: Zhou, Xun, et al.
Publicado: (2023)

A prospective cohort study of rituximab in the treatment of refractory nephrotic syndrome
por: Xu, Jing, et al.
Publicado: (2021)

The Role and Mechanism of Lysine Methyltransferase and Arginine Methyltransferase in Kidney Diseases
por: Zhou, Xun, et al.
Publicado: (2022)

An updated clinical prediction model of protein-energy wasting for hemodialysis patients
por: Chen, Si, et al.
Publicado: (2022)

Elevated expression of HDAC6 in clinical peritoneal dialysis patients and its pathogenic role on peritoneal angiogenesis
por: Shi, Yingfeng, et al.
Publicado: (2020)

The efficacy and safety of rituximab in treating childhood refractory nephrotic syndrome: A meta-analysis
por: Zhao, Zhihong, et al.
Publicado: (2015)

Rituximab shows no effect on remission in patients with refractory nephrotic syndrome: A MOOSE-compliant meta-analysis
por: Yin, Supei, et al.
Publicado: (2016)

Early Use of Rituximab in Calcineurin Inhibitor–Refractory and Steroid-Resistant Nephrotic Syndrome
por: Sinha, Rajiv, et al.
Publicado: (2020)

Rituximab therapy in adults with steroid-dependent nephrotic syndrome
por: Zhong, Hongzhen, et al.
Publicado: (2019)

Rituximab for nephrotic syndrome in children
por: Iijima, Kazumoto, et al.
Publicado: (2016)

The prognosis and risk factors of baseline high peritoneal transporters on patients with peritoneal dialysis
por: Huang, Guansen, et al.
Publicado: (2021)

Hypokalemia after rituximab administration in nephrotic syndrome: two case reports
por: Song, Yiyun, et al.
Publicado: (2023)

Acute kidney injury due to thrombotic microangiopathy in a patient with primary Sjögren’s syndrome
por: Wang, Yi, et al.
Publicado: (2022)

Rituximab Treatment for Nephrotic Syndrome in Children
por: Iijima, Kazumoto, et al.
Publicado: (2014)

Effectiveness of rituximab in nephrotic syndrome treatment
por: Popko, Katarzyna, et al.
Publicado: (2017)

Rituximab May Have Positive Effect on Refractory Nephrotic Syndrome: A Meta-Analysis of Randomized Trials
por: Lin, Jingjing, et al.
Publicado: (2022)

Rituximab Use in the Management of Childhood Nephrotic Syndrome
por: Kallash, Mahmoud, et al.
Publicado: (2019)

The Role and Mechanism of Histone Deacetylases in Acute Kidney Injury
por: Zhou, Xun, et al.
Publicado: (2021)

Analysis of risk factors and outcome in peritoneal dialysis patients with early-onset peritonitis: a multicentre, retrospective cohort study
por: Ma, Xiaoyan, et al.
Publicado: (2020)

Retracted: Rituximab May Have Positive Effect on Refractory Nephrotic Syndrome: A Meta-Analysis of Randomized Trials
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Systematic Review and Meta-Analysis of Rituximab for Steroid-Dependent or Frequently Relapsing Nephrotic Syndrome in Children
por: Gao, Xia, et al.
Publicado: (2021)

Efficacy and Safety of Rituximab in Chinese Children With Refractory Anti-NMDAR Encephalitis
por: Dou, Xiangjun, et al.
Publicado: (2020)

Clinical outcomes, quality of life, and costs evaluation of peritoneal dialysis management models in Shanghai Songjiang District: a multi-center and prospective cohort study
por: Ma, Xiaoyan, et al.
Publicado: (2021)

Circulating Anti-Rituximab Antibodies Do Not Affect Response to Rituximab in Steroid-Dependent Nephrotic Syndrome
por: Angeletti, Andrea, et al.
Publicado: (2022)

Pharmacologic Inhibition of Histone Deacetylase 6 Prevents the Progression of Chlorhexidine Gluconate-Induced Peritoneal Fibrosis by Blockade of M2 Macrophage Polarization
por: Shi, Yingfeng, et al.
Publicado: (2022)

Blockade of Autophagy Prevents the Progression of Hyperuricemic Nephropathy Through Inhibiting NLRP3 Inflammasome-Mediated Pyroptosis
por: Hu, Yan, et al.
Publicado: (2022)

Rituximab in idiopathic nephrotic syndrome: still waiting for stronger evidences
por: Belangero, Vera Maria Santoro
Publicado: (2023)

All-case Japanese post-marketing surveillance of the real-world safety and efficacy of rituximab treatment in patients with refractory nephrotic syndrome
por: Kobayashi, Mana, et al.
Publicado: (2021)

Intravenous Immunoglobulin and Methylprednisolone Refractory Multisystem Inflammatory Syndrome in Children (MIS-C) in Steroid-Dependent Nephrotic Syndrome Following Rituximab
por: Pal, Priyankar, et al.
Publicado: (2022)

Anti-rituximab antibodies in patients with refractory autoimmune nodopathy with anti-neurofascin-155 antibody
por: Bai, Yunfei, et al.
Publicado: (2023)

Successful Treatment of New-Onset Pediatric Nephrotic Syndrome With Rituximab as a First-Line Therapy
por: Zhang, Xiaojing, et al.
Publicado: (2022)

Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome
por: Counsilman, Clare E., et al.
Publicado: (2015)

Rituximab is not a “magic drug” in post-transplant recurrence of nephrotic syndrome
por: Grenda, Ryszard, et al.
Publicado: (2016)

Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials
por: Iijima, Kazumoto, et al.
Publicado: (2017)

The efficacy and safety of rituximab in treating childhood nephrotic syndrome: an Italian perspective
por: Maratea, Dario, et al.
Publicado: (2016)

Blockade of Autophagy Prevents the Development and Progression of Peritoneal Fibrosis
por: Shi, Yingfeng, et al.
Publicado: (2021)

A rare case of crescentic glomerulonephritis with monoclonal IgG deposits
por: Ma, Xiaoyan, et al.
Publicado: (2021)

Protocol for an open-label, single-arm, multicentre clinical study to evaluate the efficacy and safety of rituximab in the first episode of paediatric idiopathic nephrotic syndrome
por: Liu, Jialu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s0dgu09qqchqapkevacs63adff